Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.

J Neurol Neurosurg Psychiatry. 2019 Jan 13. pii: jnnp-2018-319831. doi: 10.1136/jnnp-2018-319831. [Epub ahead of print]

PMID:
30636699
2.

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.

Yamout BI, El-Ayoubi NK, Nicolas J, El Kouzi Y, Khoury SJ, Zeineddine MM.

J Immunol Res. 2018 Nov 12;2018:9084759. doi: 10.1155/2018/9084759. eCollection 2018.

3.

Gadoterate Meglumine Administration in Multiple Sclerosis has no Effect on the Dentate Nucleus and the Globus Pallidus Signal Intensities.

Hannoun S, Issa R, El Ayoubi NK, Haddad R, Baalbaki M, Yamout BI, Khoury SJ, Hourani R.

Acad Radiol. 2018 Dec 5. pii: S1076-6332(18)30525-7. doi: 10.1016/j.acra.2018.11.010. [Epub ahead of print]

PMID:
30527456
4.

The Bayesian risk estimate at onset (BREMSO) correlates with cognitive and physical disability in patients with early multiple sclerosis.

Said M, El Ayoubi NK, Hannoun S, Haddad R, Saba L, Jalkh Y, Yamout BI, Khoury SJ.

Mult Scler Relat Disord. 2018 Nov;26:96-102. doi: 10.1016/j.msard.2018.09.003. Epub 2018 Sep 13.

PMID:
30243236
5.

Gadolinium effect on thalamus and whole brain tissue segmentation.

Hannoun S, Baalbaki M, Haddad R, Saaybi S, El Ayoubi NK, Yamout BI, Khoury SJ, Hourani R.

Neuroradiology. 2018 Nov;60(11):1167-1173. doi: 10.1007/s00234-018-2082-5. Epub 2018 Aug 21.

PMID:
30128599
6.

Efficacy and safety of natalizumab extended interval dosing.

Yamout BI, Sahraian MA, Ayoubi NE, Tamim H, Nicolas J, Khoury SJ, Zeineddine MM.

Mult Scler Relat Disord. 2018 Aug;24:113-116. doi: 10.1016/j.msard.2018.06.015. Epub 2018 Jul 5.

PMID:
29982107
7.

Multiple Sclerosis.

Yamout BI, Alroughani R.

Semin Neurol. 2018 Apr;38(2):212-225. doi: 10.1055/s-0038-1649502. Epub 2018 May 23. Review.

PMID:
29791948
8.

Effectiveness of alternative dose fingolimod for multiple sclerosis.

Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I.

Neurol Clin Pract. 2018 Apr;8(2):102-107. doi: 10.1212/CPJ.0000000000000434.

PMID:
29708225
9.

Alternative diagnoses in patients referred to specialized centers for suspected MS.

Yamout BI, Khoury SJ, Ayyoubi N, Doumiati H, Fakhreddine M, Ahmed SF, Tamim H, Al-Hashel JY, Behbehani R, Alroughani R.

Mult Scler Relat Disord. 2017 Nov;18:85-89. doi: 10.1016/j.msard.2017.09.016. Epub 2017 Sep 21.

PMID:
29141828
10.

Radiologically isolated syndrome and multiple sclerosis.

Yamout B, Al Khawajah M.

Mult Scler Relat Disord. 2017 Oct;17:234-237. doi: 10.1016/j.msard.2017.08.016. Epub 2017 Aug 31. Review.

PMID:
29055465
11.

Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.

Yamout BI, Said M, Hannoun S, Zeineddine M, Massouh J, Khoury SJ.

J Neurol Sci. 2017 Sep 15;380:79-81. doi: 10.1016/j.jns.2017.07.014. Epub 2017 Jul 9.

PMID:
28870594
12.

Letter to the editor.

Yamout BI, Zeineddine MM.

Mult Scler. 2018 Mar;24(3):363. doi: 10.1177/1352458517717091. Epub 2017 Jul 27. No abstract available.

PMID:
28747148
13.

Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder.

Yamout BI, Beaini S, Zeineddine MM, Akkawi N.

Mult Scler. 2017 Aug;23(9):1297-1300. doi: 10.1177/1352458517694086. Epub 2017 Apr 10.

PMID:
28391740
14.

Effect of Vitamin D Replacement on Cognition in Multiple Sclerosis Patients.

Darwish H, Haddad R, Osman S, Ghassan S, Yamout B, Tamim H, Khoury S.

Sci Rep. 2017 Apr 4;7:45926. doi: 10.1038/srep45926.

15.

Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks.

Alroughani R, Altintas A, Al Jumah M, Sahraian M, Alsharoqi I, AlTahan A, Daif A, Dahdaleh M, Deleu D, Fernandez O, Grigoriadis N, Inshasi J, Karabudak R, Taha K, Totolyan N, Yamout BI, Zakaria M, Bohlega S.

Mult Scler Int. 2016;2016:1034912. doi: 10.1155/2016/1034912. Epub 2016 Dec 18. Review.

16.

Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.

Yamout BI, Abou Zeid N, Taha AJ, Zeineddine MM, Khoury SJ.

Mult Scler Relat Disord. 2016 Sep;9:122-4. doi: 10.1016/j.msard.2016.07.012. Epub 2016 Jul 25.

PMID:
27645358
17.

Vitamin D receptor biochemical and genetic profiling and HLA-class II genotyping among Lebanese with multiple sclerosis - A pilot study.

Yamout B, Karaky NM, Mahfouz RA, Jaber F, Estaitieh N, Shamaa D, Abbas F, Hoteit R, Daher RT.

J Neuroimmunol. 2016 Apr 15;293:59-64. doi: 10.1016/j.jneuroim.2016.02.008. Epub 2016 Feb 15.

PMID:
27049563
18.

JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study.

Alroughani R, Akhtar S, Ahmed SF, Khoury SJ, Al-Hashel JY, Sahraian MA, Al Jumah M, Zeineddine M, Farhat S, Doumiati H, Yamout BI.

J Neurol Sci. 2016 Jan 15;360:61-5. doi: 10.1016/j.jns.2015.11.044. Epub 2015 Nov 24.

PMID:
26723975
19.

Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.

Yamout BI, Zeineddine MM, Tamim H, Khoury SJ.

J Neuroimmunol. 2015 Dec 15;289:93-7. doi: 10.1016/j.jneuroim.2015.10.015. Epub 2015 Oct 26.

PMID:
26616877
20.

Safety and efficacy of reduced fingolimod dosage treatment.

Yamout BI, Zeineddine MM, Sawaya RA, Khoury SJ.

J Neuroimmunol. 2015 Aug 15;285:13-5. doi: 10.1016/j.jneuroim.2015.05.012. Epub 2015 May 15.

PMID:
26198913
21.

Functional clinical outcomes in multiple sclerosis: Current status and future prospects.

Karabudak R, Dahdaleh M, Aljumah M, Alroughani R, Alsharoqi IA, AlTahan AM, Bohlega SA, Daif A, Deleu D, Amous A, Inshasi JS, Rieckmann P, Sahraian MA, Yamout BI.

Mult Scler Relat Disord. 2015 May;4(3):192-201. doi: 10.1016/j.msard.2015.03.004. Epub 2015 Mar 23. Review.

PMID:
26008936
22.

Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS).

Yamout B, Alroughani R, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J, Hashem S, Alsharoqi I, Sahraian M, Khoury S, Alkawi Z, Koussa S, Zakaria M, Al Khaburi J, Alsaadi T, Bohlega S.

Curr Med Res Opin. 2015;31(7):1349-61. doi: 10.1185/03007995.2015.1047750. Epub 2015 May 29.

PMID:
25946578
23.

Epstein-Barr Virus and Human herpes virus 6 Type A DNA Enhance IL-17 Production in Mice.

Rahal EA, Hajjar H, Rajeh M, Yamout B, Abdelnoor AM.

Viral Immunol. 2015 Jun;28(5):297-302. doi: 10.1089/vim.2014.0129. Epub 2015 Apr 14.

PMID:
25870901
24.

Risk factors for multiple sclerosis and associations with anti-EBV antibody titers.

Mouhieddine TH, Darwish H, Fawaz L, Yamout B, Tamim H, Khoury SJ.

Clin Immunol. 2015 May;158(1):59-66. doi: 10.1016/j.clim.2015.03.011. Epub 2015 Mar 21.

PMID:
25805657
25.

Spontaneous intracranial hypotension syndrome treated with fludrocortisone.

Rizk M, El Khatib M, Yamout B, Hujeily E, Ayoub S, Ayoub C, Skaf G.

A A Case Rep. 2015 Jan 1;4(1):8-11. doi: 10.1213/XAA.0000000000000105.

PMID:
25612272
26.

Impact of living and socioeconomic characteristics on cardiovascular risk in ischemic stroke patients.

Amarenco P, Abboud H, Labreuche J, Arauz A, Bryer A, Lavados PM, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E; OPTIC Registry Investigators.

Int J Stroke. 2014 Dec;9(8):1065-72. doi: 10.1111/ijs.12290. Epub 2014 Jun 12.

PMID:
24923430
27.

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.

Alroughani RA, Aref HM, Bohlega SA, Dahdaleh MP, Feki I, Al Jumah MA, Al-Kawi MZ, Koussa SF, Sahraian MA, Alsharoqi IA, Yamout BI.

BMC Neurol. 2014 Feb 12;14:27. doi: 10.1186/1471-2377-14-27. Review.

28.

Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries.

Aljumah M, Alroughani R, Alsharoqi I, Bohlega SA, Dahdaleh M, Deleu D, Esmat K, Khalifa A, Sahraian MA, Szólics M, Altahan A, Yamout BI, Rieckmann P, Daif A.

Mult Scler Int. 2013;2013:952321. doi: 10.1155/2013/952321. Epub 2013 Dec 17.

29.

Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region.

Al Tahan AM, Alsharoqi I, Bohlega SA, Dahdaleh M, Daif A, Deleu D, Esmat K, Giampaolo D, Freedman MS, Gwilt M, Hosny H, Inshasi JS, Aljumah M, Khalifa A, Pakdaman H, Szólics M, Yamout BI, Sahraian MA, Zakaria MF.

Int J Neurosci. 2014 Sep;124(9):635-41. doi: 10.3109/00207454.2013.865620. Epub 2013 Dec 18. Review.

PMID:
24228830
30.

Multiple sclerosis in the Levant: a regional consensus statement.

Yamout B, El-Salem K, Gebeily S, Khoury S, Abu Zeid N, Hamoulila K, Alhalabi MS, Hasan ZN, Al Hamadani H, Hamoodi H, Al Omar A, Dahdaleh M.

Int J Neurosci. 2014 May;124(5):377-82. doi: 10.3109/00207454.2013.833198. Epub 2013 Sep 13.

PMID:
23927564
31.

Mean contact quotient using electroglottography in patients with multiple sclerosis.

Yamout B, Al-Zaghal Z, El-Dahouk I, Farhat S, Sibai A, Hamdan AL.

J Voice. 2013 Jul;27(4):506-11. doi: 10.1016/j.jvoice.2012.10.016. Epub 2013 Apr 10.

PMID:
23583207
32.

Consensus guidelines for the diagnosis and treatment of multiple sclerosis.

Yamout B, Alroughani R, Al-Jumah M, Khoury S, Abouzeid N, Dahdaleh M, Alsharoqi I, Inshasi J, Hashem S, Zakaria M, ElKallab K, Alsaadi T, Tawfeek T, Bohlega S.

Curr Med Res Opin. 2013 Jun;29(6):611-21. doi: 10.1185/03007995.2013.787979. Epub 2013 Apr 22.

PMID:
23514115
33.

Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis.

Yamout B, Issa Z, Herlopian A, El Bejjani M, Khalifa A, Ghadieh AS, Habib RH.

Eur J Neurol. 2013 May;20(5):756-64. doi: 10.1111/ene.12046. Epub 2013 Jan 8.

PMID:
23294397
34.

Voice-related quality of life in patients with multiple sclerosis.

Hamdan AL, Farhat S, Saadeh R, El-Dahouk I, Sibai A, Yamout B.

Autoimmune Dis. 2012;2012:143813. doi: 10.1155/2012/143813. Epub 2012 Oct 2.

35.

Demographics, socio-economic characteristics, and risk factor prevalence in patients with non-cardioembolic ischaemic stroke in low- and middle-income countries: the OPTIC registry.

Abboud H, Labreuche J, Arauz A, Bryer A, Lavados PG, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E, Amarenco P; OPTIC Registry Investigators.

Int J Stroke. 2013 Oct;8 Suppl A100:4-13. doi: 10.1111/j.1747-4949.2012.00893.x. Epub 2012 Sep 13.

PMID:
22974118
36.

Authors' reply to 'Report of extracranial venous stenosis in relapsing-remitting multiple sclerosis patients'.

Yamout B, Herlopian A, Issa Z, Habib RH, Fawaz A, Salame J, Wadih A, Awdeh H, Muallem N, Raad R, Al-Kutoubi A.

Mult Scler. 2011 May;17(5):643-644. doi: 10.1177/1352458511400478. No abstract available.

PMID:
28071243
37.

The importance of quality-of-life assessment in the management of patients with multiple sclerosis. Recommendations from the Middle East MS Advisory Group.

Al-Tahan AM, Al-Jumah MA, Bohlega SM, Al-Shammari SN, Al-Sharoqi IA, Dahdaleh MP, Hosny HM, Yamout BI.

Neurosciences (Riyadh). 2011 Apr;16(2):109-13.

PMID:
21427658
38.

Will new injection devices for interferon β-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East.

Deleu D, Alsharoqi I, Al Jumah MA, Al Tahan AR, Bohlega S, Dahdaleh M, Inshasi J, Khalifa A, Szólics M, Yamout BI.

Int J Neurosci. 2011 Apr;121(4):171-5. doi: 10.3109/00207454.2010.541572. Review.

PMID:
21329472
39.

Extracranial venous stenosis is an unlikely cause of multiple sclerosis.

Yamout B, Herlopian A, Issa Z, Habib RH, Fawaz A, Salame J, Wadih A, Awdeh H, Muallem N, Raad R, Al-Kutoubi A.

Mult Scler. 2010 Nov;16(11):1341-8. doi: 10.1177/1352458510385268.

PMID:
21041329
40.

Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.

Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan R, Kreidieh NM, El-Sabban M, Bazarbachi A.

J Neuroimmunol. 2010 Oct 8;227(1-2):185-9. doi: 10.1016/j.jneuroim.2010.07.013. Epub 2010 Aug 21.

PMID:
20728948
41.

Prognostic factors of multiple sclerosis in Lebanon.

Yamout B, Itani S, Arabi A, Hamzeh D, Yaghi S.

Int J Neurosci. 2010 Mar;120(3):206-10. doi: 10.3109/00207450903464587.

PMID:
20374088
42.

Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group.

Yamout BI, Dahdaleh M, Al Jumah MA, Al-Shammri S, Al Sharoqi I, Al-Tahan AR, Bohlega S, Deleu D, Inshasi J, Khalifa A, Szólics M.

Int J Neurosci. 2010 Apr;120(4):273-9. doi: 10.3109/00207450903541087.

PMID:
20374075
43.

Myasthenia gravis developing in a patient with CNS lymphoma.

Masroujeh R, Otrock ZK, Yamout B, Jabbour MN, Bazarbachi A.

Int J Hematol. 2010 Apr;91(3):522-4. doi: 10.1007/s12185-010-0503-2. Epub 2010 Feb 9.

PMID:
20140781
44.

The effect of war stress on multiple sclerosis exacerbations and radiological disease activity.

Yamout B, Itani S, Hourany R, Sibaii AM, Yaghi S.

J Neurol Sci. 2010 Jan 15;288(1-2):42-4. doi: 10.1016/j.jns.2009.10.012. Epub 2009 Nov 4.

PMID:
19892371
45.

Celiac disease, Behçet, and idiopathic thrombocytopenic purpura in siblings of a patient with multiple sclerosis.

Yamout B, Usta J, Itani S, Yaghi S.

Mult Scler. 2009 Nov;15(11):1368-71. doi: 10.1177/1352458509345908. Epub 2009 Oct 13.

PMID:
19825890
46.

Vocal symptoms and acoustic changes in relation to the expanded disability status scale, duration and stage of disease in patients with multiple sclerosis.

Yamout B, Fuleihan N, Hajj T, Sibai A, Sabra O, Rifai H, Hamdan AL.

Eur Arch Otorhinolaryngol. 2009 Nov;266(11):1759-65. doi: 10.1007/s00405-009-1003-y. Epub 2009 Jun 10.

PMID:
19513739
47.

MR imaging findings in autosomal recessive hereditary spastic paraplegia.

Hourani R, El-Hajj T, Barada WH, Hourani M, Yamout BI.

AJNR Am J Neuroradiol. 2009 May;30(5):936-40. doi: 10.3174/ajnr.A1483. Epub 2009 Feb 4.

48.

Biosimilars: opinion of an expert panel in the Middle East.

Bohlega S, Al-Shammri S, Al Sharoqi I, Dahdaleh M, Gebeily S, Inshasi J, Khalifa A, Pakdaman H, Szólics M, Yamout B.

Curr Med Res Opin. 2008 Oct;24(10):2897-903. doi: 10.1185/03007990802381554 . Epub 2008 Sep 2. Review.

PMID:
18768104
49.

Motor variant of chronic inflammatory demyelinating polyneuropathy in a child.

Sinno DD, Darras BT, Yamout BI, Rebeiz JG, Mikati MA.

Pediatr Neurol. 2008 Jun;38(6):426-9. doi: 10.1016/j.pediatrneurol.2008.02.008.

PMID:
18486826
50.

Predictors of bone density in ambulatory patients on antiepileptic drugs.

El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA.

Bone. 2008 Jul;43(1):149-155. doi: 10.1016/j.bone.2008.03.002. Epub 2008 Mar 15.

PMID:
18467202

Supplemental Content

Loading ...
Support Center